These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 21784859)

  • 81. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
    Di Nardo A; Wertz MH; Kwiatkowski E; Tsai PT; Leech JD; Greene-Colozzi E; Goto J; Dilsiz P; Talos DM; Clish CB; Kwiatkowski DJ; Sahin M
    Hum Mol Genet; 2014 Jul; 23(14):3865-74. PubMed ID: 24599401
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Rheb is essential for murine development.
    Goorden SM; Hoogeveen-Westerveld M; Cheng C; van Woerden GM; Mozaffari M; Post L; Duckers HJ; Nellist M; Elgersma Y
    Mol Cell Biol; 2011 Apr; 31(8):1672-8. PubMed ID: 21321084
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.
    Delgoffe GM; Pollizzi KN; Waickman AT; Heikamp E; Meyers DJ; Horton MR; Xiao B; Worley PF; Powell JD
    Nat Immunol; 2011 Apr; 12(4):295-303. PubMed ID: 21358638
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.
    Wolff NC; Vega-Rubin-de-Celis S; Xie XJ; Castrillon DH; Kabbani W; Brugarolas J
    Mol Cell Biol; 2011 May; 31(9):1870-84. PubMed ID: 21383064
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Evaluating the mTOR Pathway in Physiological and Pharmacological Settings.
    Hong S; Inoki K
    Methods Enzymol; 2017; 587():405-428. PubMed ID: 28253969
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Amino Acid-Mediated Intracellular Ca
    Amemiya Y; Nakamura N; Ikeda N; Sugiyama R; Ishii C; Maki M; Shibata H; Takahara T
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34198993
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size.
    Saci A; Cantley LC; Carpenter CL
    Mol Cell; 2011 Apr; 42(1):50-61. PubMed ID: 21474067
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 89. mTOR direct interactions with Rheb-GTPase and raptor: sub-cellular localization using fluorescence lifetime imaging.
    Yadav RB; Burgos P; Parker AW; Iadevaia V; Proud CG; Allen RA; O'Connell JP; Jeshtadi A; Stubbs CD; Botchway SW
    BMC Cell Biol; 2013 Jan; 14():3. PubMed ID: 23311891
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Identification of mechanically regulated phosphorylation sites on tuberin (TSC2) that control mechanistic target of rapamycin (mTOR) signaling.
    Jacobs BL; McNally RM; Kim KJ; Blanco R; Privett RE; You JS; Hornberger TA
    J Biol Chem; 2017 Apr; 292(17):6987-6997. PubMed ID: 28289099
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Design of negative-regulating proteins of Rheb/mTORC1 with much-reduced sizes of the tuberous sclerosis protein complex.
    Fu W; Wu G
    Protein Sci; 2023 Aug; 32(8):e4731. PubMed ID: 37462942
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.
    Wen ZH; Su YC; Lai PL; Zhang Y; Xu YF; Zhao A; Yao GY; Jia CH; Lin J; Xu S; Wang L; Wang XK; Liu AL; Jiang Y; Dai YF; Bai XC
    Oncogene; 2013 Jan; 32(2):160-70. PubMed ID: 22349822
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
    Mavrakis KJ; Zhu H; Silva RL; Mills JR; Teruya-Feldstein J; Lowe SW; Tam W; Pelletier J; Wendel HG
    Genes Dev; 2008 Aug; 22(16):2178-88. PubMed ID: 18708578
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR.
    Wagner RJ; Martin KA; Powell RJ; Rzucidlo EM
    Am J Physiol Cell Physiol; 2010 Jul; 299(1):C119-27. PubMed ID: 20375271
    [TBL] [Abstract][Full Text] [Related]  

  • 95. TSC2 regulates lysosome biogenesis via a non-canonical RAGC and TFEB-dependent mechanism.
    Alesi N; Akl EW; Khabibullin D; Liu HJ; Nidhiry AS; Garner ER; Filippakis H; Lam HC; Shi W; Viswanathan SR; Morroni M; Ferguson SM; Henske EP
    Nat Commun; 2021 Jul; 12(1):4245. PubMed ID: 34253722
    [TBL] [Abstract][Full Text] [Related]  

  • 96. mTOR in podocyte function: is rapamycin good for diabetic nephropathy?
    Lu MK; Gong XG; Guan KL
    Cell Cycle; 2011 Oct; 10(20):3415-6. PubMed ID: 22067710
    [No Abstract]   [Full Text] [Related]  

  • 97. Intestinal cell kinase (ICK) promotes activation of mTOR complex 1 (mTORC1) through phosphorylation of Raptor Thr-908.
    Wu D; Chapman JR; Wang L; Harris TE; Shabanowitz J; Hunt DF; Fu Z
    J Biol Chem; 2012 Apr; 287(15):12510-9. PubMed ID: 22356909
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Genetic dissection of Ragulator structure and function in amino acid-dependent regulation of mTORC1.
    Nada S; Okada M
    J Biochem; 2020 Dec; 168(6):621-632. PubMed ID: 32653916
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
    Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
    IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
    [TBL] [Abstract][Full Text] [Related]  

  • 100. TSC2: filling the GAP in the mTOR signaling pathway.
    Li Y; Corradetti MN; Inoki K; Guan KL
    Trends Biochem Sci; 2004 Jan; 29(1):32-8. PubMed ID: 14729330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.